Cargando…

Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil

OBJECTIVES: In Brazil, imatinib mesylate is supplied as the first-line therapy for chronic myeloid leukemia in the chronic phase through the public universal healthcare program, Sistema Único de Saúde (SUS). We studied the socio-demographic factors that influenced therapy success in a population in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rego, Monica Napoleão Fortes, Metze, Konradin, Lorand-Metze, Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2015
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449460/ https://www.ncbi.nlm.nih.gov/pubmed/26039947 http://dx.doi.org/10.6061/clinics/2015(05)03

Ejemplares similares

Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes
por: Vido, Joyce R, et al.
Publicado: (2011)

Spontaneous Apoptosis in Chronic Lymphocytic Leukemia Is Not an Independent Prognostic Factor for Stability of Disease When Compared with Combined AgNOR and TTM Scores
por: Metze, Konradin, et al.
Publicado: (2005)

Using Antigen Expression of Leukemic Cells for a Fast Screening of Acute Promyelocytic Leukemia by Flow Cytometry
por: Ceni-Silva, Vitória, et al.
Publicado: (2021)

Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors
por: Reis-Alves, Suiellen C, et al.
Publicado: (2015)

Goodness-of-Fit of the Fractal Dimension as a Prognostic Factor
por: Metze, Konradin, et al.
Publicado: (2009)

The Fractal Dimension of Nuclear Chromatin as a Prognostic Factor in Acute Precursor B Lymphoblastic Leukemia
por: Adam, Randall L., et al.
Publicado: (2006)

Proliferation in Non-Hodgkin’S Lymphomas and Its Prognostic Value Related to Staging Parameters
por: Lorand‐Metze, Irene, et al.
Publicado: (2004)

Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
por: Moura, Muriel Silva, et al.
Publicado: (2019)

Molecular characteristics and chromatin texture features in acute promyelocytic leukemia
por: De Mello, Mariana R B, et al.
Publicado: (2012)

Bureaucrats, researchers, editors, and the impact factor ‐ a vicious circle that is detrimental to science
por: Metze, Konradin
Publicado: (2010)

Fractal dimension of chromatin: potential molecular diagnostic applications for cancer prognosis
por: Metze, Konradin
Publicado: (2013)

Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores
por: Reis-Alves, Suiellen C., et al.
Publicado: (2013)

Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up
por: PAGNANO, KATIA BORGIA BARBOSA, et al.
Publicado: (2016)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
por: Machado, Melissa Pereira, et al.
Publicado: (2011)

Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia
por: Guevara, Gonzalo, et al.
Publicado: (2012)

Using Non-Additive Entropy to Enhance Convolutional Neural Features for Texture Recognition
por: Florindo, Joao, et al.
Publicado: (2021)

Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib
por: Fang, Baijun, et al.
Publicado: (2011)

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma
por: Ferro, Daniela P., et al.
Publicado: (2011)

The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns
por: Borges-Almeida, Eliane, et al.
Publicado: (2011)

Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center
por: Moura, Ariella Cássia de, et al.
Publicado: (2019)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Classification of Thyroid Follicular Lesions Based on Nuclear Texture Features—Lesion Size Matters
por: Metze, Konradin, et al.
Publicado: (2010)

Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
por: Aïssata, Tolo Diebkilé, et al.
Publicado: (2013)

Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms
por: Scopim-Ribeiro, Renata, et al.
Publicado: (2016)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
por: Serpa, Mariana, et al.
Publicado: (2010)

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups
por: Zehra, Samreen, et al.
Publicado: (2016)

A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes
por: Vido-Marques, J. R., et al.
Publicado: (2020)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

No contribution of GSTM1 and GSTT1 null genotypes to the risk of neutropenia due to benzene exposure in Southeastern Brazil
por: Lima, Carmen Silvia Passos, et al.
Publicado: (2009)

Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached
por: Breccia, Massimo
Publicado: (2020)

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
por: Estrada, Natalia, et al.
Publicado: (2021)

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
por: Kok, Chung H., et al.
Publicado: (2023)

Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells
por: da Rocha, M M, et al.
Publicado: (2011)

Part 2: Myelodysplastic syndromes – classification systems
por: Lorand-Metze, Irene, et al.
Publicado: (2018)

Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol
por: Pagnano, Kátia B. Barbosa, et al.
Publicado: (2010)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
por: Ito, Kyoko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_th112ibqkdeeag06n08gha611k